Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization- Cost-Effectiveness Versus Aflibercept
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2123
https://www.valueinhealthjournal.com/article/S1098-3015(14)04053-4/fulltext
Title :
Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization- Cost-Effectiveness Versus Aflibercept
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04053-4&doi=10.1016/j.jval.2014.08.2123
First page :
A608
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1587